The FDA reviewed risks and loosened the label on testosterone replacement therapy (TRT) following an attempt by the Trump administration to reverse its decline.
Steady: 0 in the last 7 days
Updated oct 24
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA reviewed risks and loosened the label on testosterone replacement therapy (TRT) following an attempt by the Trump administration to reverse its decline.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The Pentagon is issuing screening guidelines for low testosterone, linking it to national defense readiness, following discussions involving Brian Christine and Fox News.Sub-event
Administration pushes for regulatory changes to TRT and defense secretary implements mandatory testosterone screening.1 source
- Policy views clash with scientific consensus on T therapy.Sub-event
FDA revises TRT labeling; Trump administration attempts to reverse testosterone decline.1 source
Keep exploring
The entities involved
- FDA
-
Testosterone
Nothing else this week.
-
Brian Christine
American physician-scientist (born 1960)
Nothing else this week.
-
Department of Health & Human Services
government department in the state of Victoria, Australia